The North American Anti-Neoplastic Agents Market size is estimated to grow at a promising rate between 2022 and 2027.
Increased cancer diagnoses, increased government financing, technical improvements, and favorable reimbursement policies contribute to the expansion of the anti-neoplastic agent market in the North American region.
For numerous solid tumors, particularly metastatic ones, anti-neoplastic drugs are combined with immunotherapy, surgery, hormone treatment, radiation, and targeted therapy. In addition, cancer's risk grows with age, and it's becoming more frequent across the world as people's standards of living change. As a result, the rising demand for anti-neoplastic agents has prompted several large pharmaceutical companies to enter the global anti-neoplastic agents market and develop more effective medications to treat a variety of cancers.
Malignant neoplasms accounted for 15% of fatalities worldwide, according to the Centres for Disease Control and Prevention (CDC), with 19.3 million new cases of cancer expected to be identified by 2025. In addition, according to the Healthcare Cost and Utilization Project (H-cup), 4.7 million hospitalizations connected with cancer in the United States, and approximately 6% of the adult population's inpatient hospital costs were caused by the hospitalization of cancer patients.
Furthermore, one aspect that promotes the Anti-neoplastic Agents Market growth is the usage of sophisticated technologies in the anti-neoplastic agents’ market.
Absenteeism of current regulatory systems, which has hampered market expansion significantly. Furthermore, some adverse effects linked with neoplastic agents will be elevated, stymie market expansion. For example, rigorous standards that top medicine companies must obey will likely hamper market expansion. In addition, the necessity for FDA clearances further restrains the Anti-neoplastic Agents Market before a medicine can be released into the market.
Market expansion is being hampered by people's lack of understanding about cancer. Furthermore, cancer's diversified character and the substantial costs associated with its development limit its spread. In addition, the Anti-neoplastic Agents Market is being held back by technical complications associated with present diagnostic techniques.
This research report on the North American Anti-neoplastic Agents market has been segmented and sub-segmented into the following categories.
By Product:
By End Users:
By Region:
The anti-neoplastic agents market in North America is dominated, with the region owning the most significant share. As a result of the typical growth of infectious illnesses, the emergence of highly developed healthcare is one of the forces propelling this region ahead. As a result, North America makes a significant contribution to the market's dominant position. Due to enhanced healthcare infrastructure and facilities, government investment, and the typically followed unhealthy lifestyle of consumers leading to chronic illnesses, it is expected to sustain market share during the projection period. In 2022, North America had the most significant market share, accounting for 34% of the total market.
The United States is expected to lead the Anti-neoplastic Agents market in North America throughout the estimated period. Obesity on a vast scale in the United States is one of the leading causes of this region's expansion. In addition, the expanding senior population across the continent plays a key role since cancer risks increase with age and reduced immunity due to rising fast-food consumption. For example, the aging population currently accounts for 16% of the total population and is expected to increase to 22% by 2040, or 84.8 million people.
Following the United States, Canada is likely to have a sizable market share. The rise of the market for pharmaceuticals to treat cancer and other diseases is being accelerated by private sector investments. The market is expanding due to increased demand for anti-neoplastic pharmaceutical agents, which has spurred pharmaceutical firms to enter the market to research and produce more effective cancer therapies.
KEY MARKET PLAYERS:
Some of the major companies dominating the market by their products and services include Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merc & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC, and AbbVie Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]